흡입 마취 시장 : 제품별, 최종 사용자별, 용도별, 지역별, 범위 및 예측

Inhalation Anesthesia Market Size And Forecast

Inhalation Anesthesia Market size was valued at USD 1.82 Billion in 2024 and is projected to reach USD 2.7 Billion by 2031 , growing at a CAGR of 5.61% from 2024 to 2031 . Global inhalation anesthesia refers to a method of delivering anesthetic agents through inhalation, inducing a reversible loss of consciousness and sensation during surgical procedures. It is widely used in surgeries to maintain sedation, particularly for patients requiring long-term or precise anesthesia control. The primary agents used include sevoflurane, isoflurane, and desflurane, administered via masks or ventilators. Inhalation anesthesia is commonly applied in hospitals and ambulatory surgical centers across various medical fields, including general surgery, orthopedics, and pediatrics.

The future of this technique looks promising, with advancements in delivery systems and the development of safer, more efficient anesthetic agents driving its continued adoption in healthcare.

Inhalation Anesthesia Market: Definition/ Overview

Inhalation anesthesia is the use of anesthetic drugs through inhalation to induce unconsciousness and pain reduction during medical procedures. These drugs are usually inhaled using a mask or breathing tube and administered directly to the patient's lungs, where they are absorbed into the bloodstream and transported to the brain, causing loss of consciousness and pain.

Furthermore, inhalation anesthesia is widely utilized in a variety of surgical procedures, including general surgeries, orthopedic surgeries, gynecological treatments, and dental surgeries. Its applications include both inpatient and outpatient settings, providing safe and effective sedation to patients of all ages.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Inhalation Anesthesia Market Dynamics

The key market dynamics that are shaping the global inhalation anesthesia market include:

Key Market Drivers:

Rising Number of Surgical Procedures

: With an aging global population and increasing prevalence of chronic diseases, the number of surgeries is rising. According to the World Health Organization (WHO), over 310 million major surgeries are performed annually, driving the demand for inhalation anesthesia in operating rooms worldwide.

Advancements in Anesthetic Agents

: The development of safer and more efficient inhalation anesthetic agents, such as sevoflurane and desflurane, has enhanced the safety profile of anesthesia. These agents reduce recovery times and post-operative complications, making them preferred choices. The global demand for sevoflurane is expected to grow at a compound annual growth rate (CAGR) of 4% through 2027.

Increasing in Outpatient Surgeries

: The growing trend toward outpatient or same-day surgeries, supported by minimally invasive techniques, is driving demand for short-acting anesthetic solutions. In the U.S., outpatient surgeries accounted for over 60% of all surgical procedures in 2023, creating a surge in demand for inhalation anesthetics.

Rising Investments in Healthcare Infrastructure

: Emerging markets, particularly in Asia-Pacific, are investing heavily in healthcare infrastructure. China alone has invested over $70 billion in healthcare expansion in 2023, boosting the demand for modern anesthetic equipment and solutions like inhalation anesthesia.

Key Challenges:

High Cost of Inhalation Anesthetic Agents

: The cost of modern anesthetic agents, such as sevoflurane and desflurane, can be prohibitive for healthcare providers, particularly in low- and middle-income countries, limiting their adoption.

Environmental Concerns

: Inhalation anesthetics are known to have a high global warming potential (GWP), contributing to climate change. The environmental impact of these agents is becoming a growing concern, prompting the healthcare industry to seek more sustainable alternatives.

Risk of Post-Operative Complications

: Although modern agents are generally safe, some patients still experience post-operative side effects such as nausea, vomiting, and respiratory issues. This can deter healthcare providers from using inhalation anesthetics in certain cases.

Strict Regulatory Requirements

: The development and approval of new anesthetic agents face stringent regulations across different countries, slowing the market's growth and increasing the cost and time associated with bringing new products to market.

Key Trends:

Shift Towards Short-Acting Anesthetics

: There is an increasing preference for short-acting inhalation anesthetics such as sevoflurane and desflurane, which offer faster recovery times and reduced post-operative complications, enhancing patient throughput and surgical efficiency.

Technological Advancements in Delivery Systems

: Innovations in anesthesia delivery systems, including advanced vaporizer technologies and automated anesthesia workstations, are improving the precision and safety of inhalation anesthesia, leading to more effective and controlled administration.

Growth of Ambulatory and Outpatient Surgeries

: The rising trend of ambulatory and outpatient surgeries is driving the demand for inhalation anesthetics that facilitate quick recovery and minimal side effects, supporting the increased volume of same-day surgical procedures.

Emergence of Eco-Friendly Anesthetic Agents

: There is a growing focus on developing environmentally friendly inhalation anesthetics with lower global warming potential (GWP) and reduced environmental impact, driven by increasing awareness of sustainability and regulatory pressures.

Global Inhalation Anesthesia Market Regional Analysis

Here is a more detailed regional analysis of the global inhalation anesthesia market:

North America:

North America is the dominant region in the inhalation anesthesia market, driven by the high volume of surgical procedures and advanced healthcare infrastructure. The United States, in particular, leads in both market size and technological advancements. According to the Centers for Disease Control and Prevention (CDC), there are approximately 50 million surgical procedures performed annually in the U.S., creating a substantial demand for inhalation anesthesia. The region's focus on innovation and safety is supported by significant investments in research and development, contributing to its leading position in the global market.

In addition, North America benefits from a well-established network of healthcare facilities and high adoption rates of advanced anesthetic technologies. The U.S. and Canada are investing heavily in upgrading medical infrastructure, with the U.S. allocating over $20 billion for healthcare improvements in 2023 alone. This investment is enhancing the availability and quality of inhalation anesthesia, ensuring that North America remains at the forefront of the market.

Asia Pacific:

Asia Pacific is the fastest-growing region in the inhalation anesthesia market, fueled by rapid healthcare advancements and expanding medical infrastructure. Countries such as China and India are experiencing significant growth due to their large population bases and increasing healthcare investments. In 2023, China's healthcare sector received over $70 billion in investments, supporting the adoption of advanced anesthesia technologies. The rising number of surgeries and the push for modern healthcare facilities are driving the demand for inhalation anesthetics in the region.

Additionally, the expanding trend of medical tourism and the increasing focus on improving healthcare access in developing countries contribute to the growth of the inhalation anesthesia market in Asia Pacific. The region is seeing rapid advancements in both public and private healthcare sectors, enhancing the availability and use of modern anesthetic solutions.

Global Inhalation Anesthesia Market: Segmentation Analysis

The Global Inhalation Anesthesia Market is segmented on the basis of Product, End User, Application, and Geography.

Inhalation Anesthesia Market, By Product

• Desflurane
• Isoflurane
• Sevoflurane

Based on Product, the Global Inhalation Anesthesia Market is segmented into Desflurane, Isoflurane, Sevoflurane. Sevoflurane is the dominant segment due to its favorable properties, including rapid onset, quick recovery, and minimal side effects, making it the preferred choice for various surgical procedures. Sevoflurane's ease of use and efficiency have established it as the leading anesthetic agent. Desflurane is the fastest-growing segment, driven by its ultra-fast onset and recovery times, which are increasingly sought after for outpatient and short-duration surgeries. The demand for desflurane is rising as healthcare providers aim for improved patient turnover and minimized anesthesia-related complications.

Inhalation Anesthesia Market, By End User

• Hospital
• Ambulatory Surgical Centers

Based on End User, the Global Inhalation Anesthesia Market is segmented into Hospital, Ambulatory Surgical Centers. Hospitals are the dominant segment due to their large volume of surgical procedures and advanced infrastructure, which necessitates the use of various anesthetic agents. However, Ambulatory surgical centers (ASCs) are the fastest-growing segment, driven by the increasing trend towards outpatient surgeries and minimally invasive procedures. ASCs are adopting inhalation anesthesia more rapidly due to its benefits in quick recovery and efficient patient throughput, reflecting a shift towards more cost-effective and patient-friendly surgical environments.

Inhalation Anesthesia Market, By Application

• Maintenance
• Induction

Based on Application, the Global Inhalation Anesthesia Market is segmented into Maintenance, Induction. Maintenance anesthesia is the dominant segment due to its critical role in sustaining anesthesia throughout lengthy surgical procedures, ensuring patient stability and comfort. Conversely, Induction anesthesia is the fastest-growing segment, driven by advancements in rapid-acting anesthetic agents that facilitate quicker onset and smoother transitions into the anesthetic state. The increasing preference for efficient and effective induction methods is reflecting the broader trend towards optimizing surgical workflows and enhancing patient experiences.

Inhalation Anesthesia Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on the Geography, the Global Inhalation Anesthesia Market are classified into North America, Europe, Asia Pacific, and Rest of World. North America is the dominant region in the inhalation anesthesia market, driven by the high volume of surgical procedures and advanced healthcare infrastructure. The United States, in particular, leads in both market size and technological advancements. Asia Pacific is the fastest-growing region in the inhalation anesthesia market, fueled by rapid healthcare advancements and expanding medical infrastructure. Countries such as China and India are experiencing significant growth due to their large population bases and increasing healthcare investments.

Key Players

• The "Global Inhalation Anesthesia Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market
• AbbVie Inc., Baxter International Inc., Dechra Pharmaceuticals PLC, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co. Ltd, Lunan Pharmaceutical Group Co. Ltd.
• Our
• market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.
• Global Inhalation Anesthesia Market: Recent Developments
• In August 2024 Baxter International announced FDA approval for its latest anesthesia delivery system, designed to improve precision and safety in administering inhalation anesthesia. The system incorporates advanced monitoring features to enhance patient care during surgeries.
• In July 2024 the European Medicines Agency approved Halofane, a new inhalation anesthetic agent by Halothane Pharma, noted for its reduced side effects and faster recovery times. This approval opens new markets across Europe and strengthens the company's product portfolio.
• In June 2024 Drager launched a state-of-the-art vaporizer for inhalation anesthesia that offers precise dose adjustments and improved patient safety. This technology is expected to streamline anesthesia management and enhance surgical outcomes in hospitals globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL INHALATION ANESTHESIA MARKET

• 1.1 Introduction of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL INHALATION ANESTHESIA MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL INHALATION ANESTHESIA MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Desflurane
• 5.3 Isoflurane
• 5.4 Sevoflurane

6 GLOBAL INHALATION ANESTHESIA MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Maintenance
• 6.3 Induction

7 GLOBAL INHALATION ANESTHESIA MARKET, BY END-USER

• 7.1 Overview
• 7.2 Hospital
• 7.3 Ambulatory Surgical Centers

8 GLOBAL INHALATION ANESTHESIA MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East And Africa

9 GLOBAL INHALATION ANESTHESIA MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 AbbVie Inc.
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Baxter International Inc.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Dechra Pharmaceuticals PLC
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Fresenius Kabi AG
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Hikma Pharmaceuticals PLC
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Jiangsu Hengrui Medicine Co. Ltd
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Lunan Pharmaceutical Group Co. Ltd
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Merck KGaA
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.7 Piramal Enterprises Limited
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Troikaa Pharmaceuticals Ltd
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research